

Supplementary Table S2. Most frequent any-grade AEs ($\geq 20\%$) across all doses and combined.

Patients with ≥ 1 AE, n (%)	FAP-IL2v once weekly dosing									
	Flat dosing				In-patient up-titration				Expansion	Combined
	Cohort 1: 5 mg (n = 3)	Cohort 2: 10 mg (n = 4)	Cohort 3: 20 mg (n = 4)	Cohort 4: 25 mg (n = 5)	Cohort 5: 20/20/35 mg (n = 5)	Cohort 6: 20/35/35 mg (n = 1)	Cohort 7: 20/25 mg (n = 5)	Cohort 8: 15/20 mg (n = 11)	Cohort 9: 15/20 mg (n = 23)	All Part A patients (N = 61)
All-grade AEs	3 (100.0)	4 (100.0)	4 (100.0)	5 (100.0)	5 (100.0)	1 (100.0)	5 (100.0)	11 (100.0)	23 (100.0)	61 (100.0)
Pyrexia	3 (100.0)	2 (50.0)	2 (50.0)	5 (100.0)	4 (80.0)	0	2 (40.0)	7 (63.6)	18 (78.3)	43 (70.5)
Chills	1 (33.3)	1 (25.0)	2 (50.0)	2 (40.0)	2 (40.0)	0	1 (20.0)	5 (45.5)	15 (65.2)	29 (47.5)
Fatigue	1 (33.3)	1 (25.0)	2 (50.0)	2 (40.0)	2 (40.0)	1 (100.0)	2 (40.0)	5 (45.5)	11 (47.8)	27 (44.3)
Asthenia	0	1 (25.0)	2 (50.0)	3 (60.0)	0	0	0	4 (36.4)	13 (56.5)	23 (37.7)
Edema peripheral	2 (66.7)	0	0	3 (60.0)	1 (20.0)	0	1 (20.0)	5 (45.5)	7 (30.4)	19 (31.1)
Nausea	2 (66.7)	2 (50.0)	2 (50.0)	2 (40.0)	3 (60.0)	0	2 (40.0)	4 (36.4)	13 (56.5)	30 (49.2)
Diarrhea	1 (33.3)	0	1 (25.0)	3 (60.0)	3 (60.0)	1 (100.0)	1 (20.0)	4 (36.4)	6 (26.1)	20 (32.8)
Constipation	2 (66.7)	1 (25.0)	2 (50.0)	0	2 (40.0)	0	2 (40.0)	4 (36.4)	6 (26.1)	19 (31.1)
Vomiting	1 (33.3)	0	1 (25.0)	1 (20.0)	2 (40.0)	0	1 (20.0)	3 (27.3)	10 (43.5)	19 (31.1)
Infusion-related reaction	2 (66.7)	2 (50.0)	2 (50.0)	3 (60.0)	5 (100.0)	1 (100.0)	4 (80.0)	8 (72.7)	14 (60.9)	41 (67.2)
Decreased appetite	2 (66.7)	1 (25.0)	3 (75.0)	1 (20.0)	2 (40.0)	0	3 (60.0)	7 (63.6)	6 (26.1)	25 (41.0)
AST increased	1 (33.3)	1 (25.0)	0	2 (40.0)	2 (40.0)	1 (100.0)	1 (20.0)	1 (9.1)	7 (30.4)	16 (26.2)
ALT increased	1 (33.3)	1 (25.0)	0	2 (40.0)	1 (20.0)	1 (100.0)	0	1 (9.1)	7 (30.4)	14 (23.0)
Blood bilirubin increased	0	0	1 (25.0)	1 (20.0)	2 (40.0)	0	0	4 (36.4)	6 (26.1)	14 (23.0)
Cough	0	0	1 (25.0)	0	1 (20.0)	0	1 (20.0)	5 (45.5)	6 (26.1)	14 (23.0)
Dyspnea	0	0	0	0	4 (80.0)	0	1 (20.0)	3 (27.3)	5 (21.7)	13 (21.3)
Rash	1 (33.3)	1 (25.0)	1 (25.0)	2 (40.0)	1 (20.0)	0	0	3 (27.3)	4 (17.4)	13 (21.3)
Anemia	0	0	0	1 (20.0)	2 (40.0)	0	2 (40.0)	5 (45.5)	7 (30.4)	17 (27.9)

AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; FAP-IL2v, fibroblast activation protein- α interleukin-2 variant.